We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bedside Scanning Device to Enable Slide-Free Pathology for Complete Surgical Tumor Removal

By LabMedica International staff writers
Posted on 15 Aug 2024

Annually, millions are diagnosed with cancer, with surgical removal being the first treatment option for solid tumors. More...

However, distinguishing tumor margins from healthy tissue during surgery poses a challenge due to insufficient visual contrast. Current practices involve pathologists examining thin sections of tumors under microscopes to examine the borders between cancer and healthy tissue, but this method is time-consuming and only inspects a small portion of the tumor. Consequently, it can take several days or even weeks to confirm whether the entire tumor has been successfully removed. Researchers are now developing a sophisticated imaging system designed to instantly scan tumors during surgical procedures and ascertain within minutes if any cancerous tissue remains after the excision.

Researchers at Tulane University (New Orleans, LA, USA) are leading a project called MAGIC-SCAN (Machine-learning Assisted Gigantic Image Cancer margin SCANner) which aims to become one of the fastest high-resolution tissue scanners in the world. This system would be capable of identifying residual cancer cells on the surface of excised organs in a matter of minutes. The scanner would be trained on a vast database of clinical scans to accurately identify cancer cells at a cellular level, producing a detailed 3D map of the tumor’s surface. The new technology combines advances in microscopy, automation, computing, and machine learning, utilizing optical-sectioning super-resolution structured illumination microscopy to achieve twice the resolution of conventional microscopes.

This cutting-edge imaging tool promises to transform cancer surgery by enabling doctors, while the patient is still under anesthesia, to verify the complete removal of cancer, potentially eliminating the need for additional surgeries. The Tulane research team has been developing this technology with a focus on prostate and colorectal cancers—two of the most challenging tumors to excise—reducing detection time to approximately 45 minutes. They have built a prototype of this groundbreaking system and are now leading efforts to address the remaining technical, computing, and engineering challenges to actualize this device within five years. Efforts are underway to enhance imaging resolution quality and develop the necessary cyberinfrastructure to manage extensive data sets required for training the machine-learning models. Furthermore, the team plans to conduct clinical validation of the device and develop versions compliant with FDA regulations.

“Currently, it can take days to weeks before a surgeon knows whether all the tumor has been removed, and our goal is to get that down to 10 minutes, while the patient is still on the table,” said J. Quincy Brown, PhD, associate professor of biomedical engineering in the Tulane School of Science and Engineering and lead researcher on the project. “If successful, our work would transform cancer surgery as we know it.”

Related Links:
Tulane University


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Multilevel Whole Blood Calibrator Set
6PLUS1
New
Silver Member
Cell and Tissue Culture Plastics
Diamond® SureGro™ Cell and Tissue Culture Plastics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.